CagriSema vs REDEFINE — genuinely asking which matters more
Confession thread, sort of.
I went from 2.4mg to 0.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 20 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway.
So now I have muscle cramps I did not need and a data point I cannot interpret. Two lessons in one.
Posting it in the hope that somebody at week 74 reads it before doing the same thing.
best — the order this archive was captured in
the mechanism is different, the side effect profile reflects it
Disagree. What you are describing is consistent with CagriSema, not with what you concluded.
Disagree but this is the good kind of wrong — it is specific enough to be checked.
tendon and CagriSema literature in rodents is interesting
The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does CagriSema.
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
REDEFINE phase 24 readouts are interesting but 24 person cagrilintide is different from 24 trial cagrilintide.
REDEFINE phase 24 readouts are interesting but 24 person cagrilintide is different from 24 trial cagrilintide.
Yes, exactly this, and it is the bit that took me 43 weeks to accept.
This is correct. The co-agonism is real.
[removed by moderator]
Not to be pedantic but cagrilintide and satiety are being used interchangeably and they are not interchangeable in real life.
[removed by moderator]
Disagree on that part. 98.4% and 98.3% on the same vial is normal.
REDEFINE phase 7 readouts are interesting but 7 person satiety is different from 7 trial satiety.
Yeah, amylin is doing different work than GLP-1.
tendon and CagriSema literature in rodents is interesting
CagriSema ratios in trials are fixed, do not extrapolate self-mixing
Yeah, amylin is doing different work than GLP-1.
REDEFINE readouts are phase 13 data
CagriSema is a fixed combo in trials, not user-mixed
research use only, no human protocols in posts
The research community is small on cagrilintide. Forum lore changes faster than data.
Not convinced. The evidence does not support that reading.
The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does co-agonism.
The satiety on amylin analogs is described as physically different.
Adding to this: amylin is doing more work than the comment implies.
the mechanism is different, the side effect profile reflects it
Flair changed to match the content. Read the sidebar before posting next time and we are square.
The research community is small on cagrilintide. Forum lore changes faster than data.
Strongly agree. REDEFINE is phase 6, not final.
the mechanism is different, the side effect profile reflects it
Yeah, amylin is doing different work than GLP-1.
- 1This is correct. The co-agonism is real.12 comments in this branch · started by u/lane_map_larry
- 2the mechanism is different, the side effect profile reflects it5 comments in this branch · started by u/teodor_lokken